Oklahoma's cannabis industry faces regulatory fatigue as lawmakers urge a pause on new rules. How might this approach affect medical marijuana businesses and patients—and what lessons can the DMV take?

New York greenlights a groundbreaking clinical trial of a THC-based oral solution, VER-01, targeting chronic sciatica pain—a move with national medical cannabis implications.

A bipartisan House bill would require the U.S. Department of Veterans Affairs to examine medical marijuana for PTSD and chronic pain—starting with an observational study.

Learn how survivor-built vetting frameworks use color-coded flags to help consumers identify ethical guides and avoid abuse.

Journalist Erica Rex urges caution: psychedelic states can open trauma and power imbalances. Here’s what ethical care, safety, and patient-centered practices should look like in the DMV.

State audit of Pennsylvania medical cannabis exposes regulatory gaps, offering critical safety lessons for East Coast patients.

MKUltra and modern psyops shape how patients judge claims. Here’s how DMV readers can vet medical marijuana delivery, dosing, and safety without falling for propaganda.

Psychedelic Alpha reports that Risk Evaluation and Mitigation Strategies are likely to shape how FDA-approved psychedelic therapies are delivered. Here’s what to watch.

Resilient resubmits MDMA-assisted therapy to FDA, Definium reports positive oral LSD Phase 3 data in GAD, and Canada funds a C$24M cannabis–brain health consortium.